Europe Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
LONDON, July 20, 2017 /PRNewswire/ -- KEY FINDINGS
The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 6.08% during the forecast years of 2017-2025.The market value is estimated to increase from $434.7 million in 2016 and reach $738.73 million by 2025.
Download the full report: https://www.reportbuyer.com/product/5012010/
MARKET INSIGHTS
The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. The market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones. The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is the leading drug in the market.
COMPETITIVE INSIGHTS
The top players in the market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A.
Download the full report: https://www.reportbuyer.com/product/5012010/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article